Not too soon for a policy statement. I am getting this question more frequently from individuals who got the J&J vaccine or their providers. Clinicians would feel more confident in the advice they give if this is backed by a policy statement grounded win science from PH agencies.
-
-
I’m struggling a little to understand this one. Why recommend re-vaccinating 10 mill+ people when there is a global scarcity of vaccine and J&J protects severe disease against variants? If it’s transmission risk why not use those resources for unvaccinated pockets in the South?
2 replies 1 retweet 3 likes -
Or why not do both? i.e assess need to re-vaccinate those who got J&J already and offer them a booster while continuing to vaccinate pockets of the south where vaccination is low. I think there's a need for clarity on booster; are they needed? If yes when and with what.
3 replies 0 retweets 5 likes -
I do believe very much in the prioritize globally argument, but that should not preclude collecting data on breakthroughs (CDC stopped) and also making a policy statement since the question is already here—at a minimum for people with kids<12 or immunocompromised family members.
1 reply 0 retweets 5 likes -
I’ve a NYT piece arguing prioritize vulnerable groups and healthcare workers globally even if it means slower rollout especially to less vulnerable, but real solution is increasing supply—to remove the dilemma. Still, symptomatic breakthrough could transmit. Needs assessment.
1 reply 0 retweets 3 likes -
To me it’s like the question over vaccinating teenagers. “Should we do it” is a correct broad question deserving discussion as well as “should we do it now given supply globally.” Anyway, I think clinicians needs CDC guidance! I don’t doubt they’re being asked.
3 replies 0 retweets 2 likes -
I agree with all your points
@zeynep, particularly the need for monitoring of all breakthrough infections w/ sequencing. Our@PreventCOVID_19 transmission study is still open (no more randomizing to delay) to look at this question in young adults. 'Ring' boosting around ...2 replies 0 retweets 1 like -
Replying to @k_stephensonMD @zeynep and
immunocompromised folks is an interesting idea, and what the individual should do when options available is a very different issue than global policy. (Why I vaccinated my own kid even though I don't think kids should be prioritized over global HCW.) My more general concern ...
1 reply 0 retweets 1 like -
Replying to @k_stephensonMD @zeynep and
is having ACIP make any policy recommendation to boost b/c that sets the tone for global prioritization and implies we have more knowledge on this than we do. I realize that is not ACIP's job (it's to provide guidance to Americans) but it's my observation as to what happens. And
1 reply 0 retweets 0 likes -
Replying to @k_stephensonMD @zeynep and
if the ACIP says J&J needs a boost (without solid data to support that), then that leaves South Africa for example in a real lurch. Should they boost their HCW w/ Pfizer, or save Pfizer for non-HCW b/c they already received J&J? I'd prefer more data discussion before policy rec.
1 reply 1 retweet 2 likes
Yeah the J&J pause here had a bigger impact in South Africa arguably, so that's the extra twist, yep, ACIP influences global policy. They may not be ready to say something now, but they should realize they will have to, and re-instate breakthrough followups esp. for symptomatic.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.